Chronic Co-Morbid Conditions in HIV+ U.S. Adults on Highly-Effective Anti-Retroviral Therapy (R21)
The summary for the Chronic Co-Morbid Conditions in HIV+ U.S. Adults on Highly-Effective Anti-Retroviral Therapy (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Chronic Co-Morbid Conditions in HIV+ U.S. Adults on Highly-Effective Anti-Retroviral Therapy (R21): Purpose. This FOA issued by National Institute of Nursing Research, National Institutes of Health, solicits Research Project Grant (R21) applications from institutions/organizations proposing mechanistic projects or interventions designed to understand or intervene in chronic co-morbid conditions common to HIV+ adults living in the U.S. who are treated with anti-retroviral therapy. These conditions may be a result of anti-retroviral therapy or the HIV disease process. These same kinds of conditions may also be common in older non-infected adults, but more information is needed on the natural history, including both biological and behavioral manifestations, and appropriate intervention when HIV+ adults are affected by conditions, such as cachexia, diabetes, kidney disease, neurological changes, cardiovascular disease or cancer. Since the advent of the protease inhibitors in 1996-1997, anti-retroviral treatment options have been evolving, including the customized combination ART. It is important to evaluate this progress and identify new opportunities for research associated with the use of anti-retroviral therapies and the association of co-morbidities of HIV+ individuals as they live through middle and old age. Research exploring these issues utilizing interdisciplinary and multidisciplinary research teams is strongly encouraged, as are research teams including underrepresented, minority, disabled, or women investigators. Mechanism of Support. This FOA will utilize the R21 grant mechanism and runs in parallel with a FOA of identical scientific scope, RFA-NR-10-001, that encourages applications under the R01 mechanism.
|Federal Grant Title:||Chronic Co-Morbid Conditions in HIV+ U.S. Adults on Highly-Effective Anti-Retroviral Therapy (R21)|
|Federal Agency Name:||National Institutes of Health|
|Grant Categories:||Education Health|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-NR-10-002|
|Type of Funding:||Grant|
|CFDA Descriptions:||Nursing Research|
|Current Application Deadline:||May 05, 2010|
|Original Application Deadline:||May 05, 2010|
|Posted Date:||Feb 04, 2010|
|Creation Date:||Feb 04, 2010|
|Archive Date:||Jun 05, 2010|
|Total Program Funding:||$1,875,000|
|Maximum Federal Grant Award:||$200,000|
|Minimum Federal Grant Award:|
|Expected Number of Awards:|
|Cost Sharing or Matching:||No|
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
- Similar Government Grants
- • Strengthening the Impact of Community Health Workers on the HIV Care Continuum in the US (...
- • Strategies to Improve Health Outcomes and to Reduce Disparities in Rural Populations (R01 ...
- • Patient Activation for Self-Management of Chronic Conditions (R21 Clinical Trial Optional)
- • Patient Activation for Self-Management of Chronic Conditions (R01 Clinical Trial Optional)
- • Omics-guided Biobehavioral Interventions for Improved Health Outcomes: A Step Forward in T...
- • Ninr Career Transition Award (K22)
- • Ruth L. Kirschstein National Research Service Award (NRSA) for Individual Predoctoral Fell...
- • NINR Mentored Research Scientist Development Award for Underrepresented or Disadvantaged I...
- More Grants from the National Institutes of Health
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
- • New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria...